Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial.
Nutrients. 2019 Oct 22;11(10). pii: E2547. doi: 10.3390/nu11102547.
Yonaga H1,2, Okada S3, Akutsu T4, Ohdaira H5, Suzuki Y6, Urashima M7.
- Gastrointestinal Cancers - mostly positive Vitamin D studies – May 2019
- Gastric Cancer 8.8 times more likely if low vitamin D – Sept 2016
- Digestive tract cancer death rates reduced a bit by a bit of vitamin D – RCT April 2019
- original study
Vitamin D Receptor and Cancers
Items in both categories Vitamin D Receptor and Cancer - Colon:
- Colon Cancer protects itself by changing the VDR and CYP3A4 genes – Dec 2022
- 14th activator of the Vitamin D Receptor – Butyrate (from gut bacteria, or supplement)
- Colon cancer risk increases 30X if you have the worst vitamin D receptor mutation – Jan 2021
- Book: Sunlight, UV, Vitamin D and Receptor, Skin and other Cancers - Dec 2020
- Colorectal Cancer Patients 2.4 X more likely to have poor Vitamin D receptors (less D to cells) – April 2020
- Colorectal cancer linked to poor Vitamin D Receptor (yet again) – Jan 2020
- Colorectal Cancer risk increases when genes reduce the vitamin D levels – Aug 2019
- Risks of Colorectal Cancer, IBD, etc slightly increased if poor Vitamin D Receptor – Aug 2018
- Cancer and the Vitamin D Receptor, a primer – Sept 2017
- Advanced Colon Cancer risk is doubled or halved with 1000 IU of Vitamin D, depends on Vitamin D Receptors – RCT May 2017
- Colon Cancer survival 3.1 X less likely if poor Vitamin D Receptor – Aug 2017
- Risk of Cancer increased if poor Vitamin D Receptor – meta-analysis of 73 studies Jan 2016
- 10 percent of colon cancer linked to Vitamin D Receptor – meta-analysis April 2012
Items in both categories Vitamin D Receptor and Cancer
- 100 years since the discovery of Vitamin D - 23 studies - 2022, 2023
- Cancers are associated with low vitamin D, poor vaccination response and perhaps poor VDR – July 2022
- Poor prognosis of solid childhood cancers 14.7 X more likely with a poor Vitamin D Receptor – July 2022
- Cancers and Vitamin D Receptors, including change with race – Feb 2021
- Needing a high level of vitamin D is a good clue that the Vitamin D Receptor is deactivated
- Vitamin D Receptor and Cancer
- Book: Sunlight, UV, Vitamin D and Receptor, Skin and other Cancers - Dec 2020
- How cancer is fought by Vitamin D (Ovarian this time) – Feb 2020
- 8 ways that Cancer might be prevented by Vitamin D - June 2019
- Cancer is leading cause of death - Vitamin D and Receptor activators help
- The Role of Resveratrol in Cancer Therapy – Dec 2017
- A poor Vitamin D Receptor is associated with many cancers (oral cancer in this case) – Jan 2019
- Overview of Vitamin D Actions in Cancer – 31 page chapter in a book – 2018
- Cancer treatment by Vitamin D sometimes is restricted by genes – Oct 2018
- Vitamin D receptor is essential for both normal and cancerous cells in the lab – June 2018
- Active Vitamin D reduces Ovarian Cancer stem cells growth by 4X (via Vitamin D receptor in lab rat) – March 2018
- Cancer and the Vitamin D Receptor, a primer – Sept 2017
- Cancer risks and Vitamin D Receptors – association is unclear – 2017
- Vitamin D, Vitamin D Receptor and Cancer – Nov 2016
- Risk of Cancer increased if poor Vitamin D Receptor – meta-analysis of 73 studies Jan 2016
- Role of Vitamin D in human Diseases and Disorders – An Overview – DBP, VDR June 2014
- Vitamin D Receptor role in Autoimmune Diseases and or cancers – Nov 2013
- Vitamin D receptor polymorphisms are risk factors for various cancers – meta-analysis Jan 2014
Items in both categories Vitamin D Receptor and Cancer - other:
- Cervical Cancer is prevented by Vitamin D, and treated if caught early (genes are important) – May 2023
- Oral Cancers - increased risk if low vitamin D or poor vitamin D genes
- Blood cell cancer is associated with a 3X worse Vitamin D Receptor – June 2019
- A poor Vitamin D Receptor is associated with many cancers (oral cancer in this case) – Jan 2019
- Endometriosis, Endometrial Cancer, and poor Vitamin D or Receptor – Aug 2018
- Thyroid Cancer rate has increased 3X in 3 decades, Vitamin D Receptor decreases, Calcium increases – Aug 2017
- Gastric Cancer 2.7 X more likely if poor Vitamin D Receptor (Chinese) – 2015
- 2X more likely to survive a form of esophageal cancer in China if have good vitamin D receptor – Feb 2017
- Multiple Myeloma (blood cell cancer) treated by vitamin D - many studies
- 2X more Thyroid Cancer malignancy if less than 15 ng of vitamin D – June 2012
- Brain cancer in 175 countries related to low UVB and low vitamin D – Oct 2010
Download the PDF from VitaminDWiki
Mainly Stomach Cancers
Some coauthors of this study previously performed the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2,000 IU/day) in 417 patients with stage I to III digestive tract cancer from the esophagus to the rectum who underwent curative surgery (UMIN000001977).
We conducted a post-hoc analysis of the AMATERASU trial to explore the effects of modification of vitamin D supplementation by histopathological characteristics on survival. Among patients with poorly differentiated adenocarcinoma, the 5-year relapse-free survival rate of patients supplemented with vitamin D was 91% compared with 63% in the placebo group (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.08 to 0.78; P = 0.017; P for interaction = 0.023).
Similarly, the 5-year overall survival rate was 92% in the vitamin D group compared with 72% in the placebo group (HR, 0.25; 95%CI, 0.07 to 0.94; P = 0.040; P for interaction = 0.012).
In contrast, there were no significant effects in other histopathological characteristics between vitamin D and placebo groups. These findings generated the hypothesis that oral vitamin D supplementation may improve both relapse-free survival and overall survival in a subgroup of patients with poorly differentiated adenocarcinoma.
From the web
- “The poorly differentiated neuroendocrine carcinoma subtype is characterized by its non-secretory, aggressive behavior and frequently grows in the gastrointestinal and genitourinary tracts [1]. The median survival of patients with this disease who have distant metastases is about five months.”
- “As a rule, an undifferentiated cancer is more malignant than a cancer of that type which is well differentiated.”